Tissue-engineered medical device

Abstract

The present invention concerns a tissue-engineered medical device, as well as a method for the production said medical device, comprising the following steps: providing a polymer scaffold comprising a mesh comprising polyglycolic acid, and a coating comprising poly-4-hydroxybutyrate; application of a cell suspension containing preferably human cells to the polymer scaffold; placement of the seeded polymer scaffold in a bioreactor and mechanical stimulation by exposure to a pulsatile flux of incremental intensity, thereby forming an extracellular matrix; mounting of the graft on a conduit stabilizer and incubation in cell culture medium; decellularisation of the graft in a washing solution; nuclease treatment of the graft; and rinsing of graft. The invention further comprises and various steps of quality control of the tissue-engineered medical device.

Claims

1. A method for production of a tissue-engineered medical device, comprising the following steps: A.) providing a polymer scaffold, said polymer scaffold comprising a substrate comprising polyglycolic acid, and a coating comprising poly-4-hydroxybutyrate (‘P4HB’); B.) application of a cell suspension containing isolated and expanded cells to the polymer scaffold, thereby producing a seeded polymer scaffold; C.) placement of the seeded polymer scaffold in a bioreactor and mechanical stimulation by exposure to a pulsatile flux of incremental intensity, thereby forming a tissue-engineered medical device comprising an extracellular matrix; D.) mounting of the tissue-engineered medical device on a conduit stabilizer and incubation under static conditions in a cell culture medium; E.) decellularisation of the tissue-engineered medical device in a washing solution comprising a detergent; F.) nuclease treatment of the tissue-engineered medical device; G.) rinsing of the tissue-engineered medical device.

2. The method for the production of a tissue-engineered medical device according to claim 1, characterized in that step A.) comprises the following steps: providing a mesh comprising polyglycolic acid (‘PGA’) as the substrate for the polymer scaffold; in a first coating step, coating the mesh with a solution containing poly-4-hydroxybutyrate; sterilizing the polymer scaffold; and incubating the polymer scaffold in a cell culture medium.

3. The method for the production of a tissue-engineered medical device according to claim 2, wherein the tissue-engineered medical device is a vascular graft, and wherein after the first coating step and prior to sterilization, the method comprises the following steps: shaping the coated mesh to a tube, thereby forming a tubular polymer scaffold; in a second coating step, coating the tubular polymer scaffold, with a solution containing poly-4-hydroxybutyrate (‘P4HB’).

4. The method for the production of a tissue-engineered medical device according to claim 3, wherein in step B.) the cell suspension containing isolated and expanded cells is applied only to an inner surface of the tubular polymer scaffold.

5. The method for the production of a tissue-engineered medical device according to claim 3, wherein after shaping the coated mesh to a tube, the method further comprises the step of fixing edges of the mesh by heating them to at least 60 degrees Celsius, thereby forming a tubular polymerscaffold.

6. The method for the production of a tissue-engineered medical device according to claim 3, wherein in the second coating step, the coating of the tubular polymer scaffold with a solution containing poly-4-hydroxybutyrate is carried out only on an outer side of the tube.

7. The method for the production of a tissue-engineered medical device according to claim 3, wherein the second coating step is carried out by spray coating.

8. The method for the production of a tissue-engineered medical device according to claim 1, wherein in step B.), the cells contained in the cell suspension are human cells selected from a group consisting of fibroblasts, mesenchymal stem cells, mononuclear cells, and endothelial progenitor cells.

9. The method for the production of a tissue-engineered medical device according to claim 8, wherein in step B.), the cells contained in the cell suspension are human cells derived from a source selected from a group consisting of bone marrow, blood, adipose tissue, amniotic fluid, chorionic villi, umbilical cord matrix, and umbilical cord blood.

10. The method for the production of a tissue-engineered medical device according to claim 8, wherein in step B.), the cells contained in the cell suspension are human fibroblasts derived from a human umbilical cord vein.

11. The method for the production of a tissue-engineered medical device according to claim 1, wherein in step B.) at least 0.5-5 million cells/cm.sup.2 are seeded on the polymer scaffold.

12. The method for the production of a tissue-engineered medical device according to claim 11, wherein in step B.) 2-4 million cells/cm.sup.2 are seeded on the polymer scaffold.

13. The method for the production of a tissue-engineered medical device according to claim 1, wherein the cell suspension applied in step B.) is prepared by a method comprising the following steps: isolation of the cells, selected from a group consisting of fibroblasts, mesenchymal stem cells, mononuclear cells, and endothelial progenitor cells; subsequently expansion of the cells, subsequently harvesting of the isolated and expanded cells; subsequently forming a cell suspension by adding a cell carrier solution comprising a gelling agent to the isolated and expanded cells.

14. The method for the production of a tissue-engineered medical device according to claim 13, wherein the cell suspension applied in step B.) is prepared by a method comprising all of the following steps: isolation of cells, wherein the cells are human cells selected from a group consisting of fibroblasts, mesenchymal stem cells, mononuclear cells, and endothelial progenitor cells, derived from a source selected from a group consisting of: bone marrow, blood, adipose tissue, amniotic fluid, chorionic villi, umbilical cord matrix, umbilical cord blood; expansion of the isolated cells in at least one culture vessel for 5-8 days; harvesting of the isolated cells; forming a cell suspension by adding a cell carrier solution comprising a gelling agent to the isolated cells.

15. The method for the production of a tissue-engineered medical device according to claim 13, wherein the cell suspension is formed by adding a cell carrier solution comprising fibrinogen and purified thrombin, to the isolated and expanded cells, wherein the cell suspension is formed by first adding purified fibrinogen to the isolated and expanded cells to form a first cell suspension, and subsequently adding purified thrombin to the first cell suspension to form a second cell suspension which then serves as the cell suspension for application to the polymer scaffold in step B.).

16. The method for the production of a tissue-engineered medical device according to claim 1, wherein the method further comprises at least one of the following steps after the step of rinsing of the tissue-engineered medical device: lyophilisation of the tissue-engineered medical device; packaging of the tissue-engineered medical device; sterilization of the tissue-engineered medical device.

17. The method for the production of a tissue-engineered medical device according to claim 16, wherein the method further comprises all of the following steps: lyophilisation of the tissue-engineered medical device; packaging of the tissue-engineered medical device; sterilization of the tissue-engineered medical device by ethylene oxide treatment.

18. The method for the production of a tissue-engineered medical device according to claim 1, wherein the method further comprises one or more of the following steps of in-process quality control: determination of a content of P4HB in the polymer scaffold, wherein thean acceptance criterion for the content of P4HB in the polymer scaffold is that the content of P4HB in the polymer scaffold is in the range of 5-95% w/w; ensuring of homologous deposition of P4HB on a mesh of the polymer scaffold; examination of cells to be seeded on the polymer scaffold prior to seeding in terms of cell identity, proliferation, viability and lack of pathogens; control of a coagulation time of the cell suspension; control of a number of cells seeded on the polymer scaffold; control of homogenous application of cells to the polymer scaffold; control of medium composition in the bioreactor; control of lactate value at each medium change in the bioreactor; control of formation of the extracellular matrix in the bioreactor.

19. The method for the production of a tissue-engineered medical device according to claim 18, wherein during a quality control of cells to be seeded on the polymer scaffold prior to seeding, a cell identity is determined via flow cytometry, and/or wherein a proliferation capacity is determined by measuring a doubling time, wherein a preferred acceptance criterion for the doubling time is less than 100 hours.

20. The method for the production of a tissue-engineered medical device according to claim 18, wherein the method further comprises all of the following steps of in-process quality control: determination of a content of P4HB in the polymer scaffold, wherein the acceptance criterion for the content of P4HB in the polymer scaffold is that the content of P4HB in the polymer scaffold is in the range of 5-95% w/w; ensuring of homologous deposition of P4HB on the mesh of the polymer scaffold; examination of cells to be seeded on the polymer scaffold prior to seeding in terms of cell identity, proliferation, viability and lack of pathogens; control of the coagulation time of the cell suspension; control of number of the cells seeded on the polymer scaffold; control of homogenous application of the cells to the polymer scaffold; control of medium composition in the bioreactor; control of lactate value at each medium change in the bioreactor; control of formation of extracellular matrix in the bioreactor by mass spectrometry by using human procollagen type I C-terminal propeptide as a suitable marker.

21. The method for the production of a tissue-engineered medical device according to claim 1, wherein the method further comprises at least one of the following steps of quality control of a finished tissue-engineered medical device: verification of sterility; measurement of endotoxin content; measurement of mycoplasma content; measurement of residual DNA content; measurement of residual water content; measurement of polymer content; measurement of hydroxyprolin content; measurement of protein content, by determining a content of extracellular matrix proteins; measurement of thickness; suture retention test; tensile strength test; burst pressure test.

22. The method for the production of a tissue-engineered medical device according to claim 21, wherein the method further comprises all of the following steps of quality control of a finished tissue-engineered medical device: verification of sterility; measurement of endotoxin content; measurement of mycoplasma content; measurement of residual DNA content; measurement of residual water content; measurement of polymer content; measurement of hydroxyprolin content; measurement of protein content by determining a content of at least one of the following proteins selected from the group consisting of: fibronectin, collagen alpha-2(I) chain, collagen alpha-2(VI) chain; and/or by determining a content of at least one of the following proteins selected from the group consisting of: superoxide dismutase, 60S acidic ribosomal protein P2, integrin alpha 5; measurement of thickness, by microscopic analysis, in a dry and/or rehydrated form, wherein an acceptance criterion for the thickness of the decellularized tissue-engineered medical device is a range of 0.1-0.6 mm in a dry form and/or 0.15-0.7 mm in a rehydrated form; suture retention test, wherein an acceptance criterion is that the tissue-engineered medical device withstands more than 0.5 N; tensile strength test, wherein an acceptance criterion is that the tissue-engineered medical device withstands more than 0.5 MPa; burst pressure test, wherein an acceptance criterion is that the tissue-engineered medical device withstands a pressure more than 150 mmHg.

23. The tissue-engineered medical device produced by the method according to claim 1.

24. The tissue-engineered medical device according to claim 23, wherein the tissue-engineered medical device is selected from the group consisting of a vascular graft, a valvular graft and a tissue patch.

25. The tissue-engineered medical device according to claim 23, wherein the tissue-engineered medical device contains a polymer scaffold comprising a PGA-mesh which comprises a coating containing P4HB and an extracellular matrix developed on the polymer scaffold, and wherein the tissue-engineered medical device comprises one or more of the following features: an endotoxin content of less than 0.29 EU/ml; a mycoplasma content below a limit of detection; a residual DNA content of less than 50 ng dsDNA per mg dry weight; a residual water content of less than 5%; a PGA content of 0-30%, and a P4HB content of 30-75% (w/w); a hydroxyprolin content of more than 5 μg/mg; a content of fibronectin of at least 100 fmol/μg, and/or a content of collagen alpha-2(I) chain of at least 200 fmol/μg, and/or a content of collagen alpha-2(VI) chain of at least 5 fmol/μg; and/or a content of superoxide dismutase of less than 3 fmol/μg, and/or a content of 60S acidic ribosomal protein P2 of less than 3 fmol/μg, and/or a content of integrin alpha-5 of less than 3 fmol/μg a thickness of 0.15-700 μm; a suture retention of at least 0.5 N; a tensile strength of at least 0.5 MPa; a burst pressure of more than 150 mmHg.

26. The tissue-engineered medical device according to claim 23 configured for use as a cardiovascular replacement graft in human or animal patients.

27. The tissue-engineered medical device according to claim 23 configured for use as a heart valve or as a patch in a human or animal patient with a defect of a cardiovascular system.

28. The tissue-engineered medical device of claim 23 configured for use in a treatment of a cardiovascular disease of a human or animal body.

29. The tissue-engineered medical device according to claim 23 configured for use in a treatment of a defect of a cavopulmonary connection in a human or animal patient.

30. The tissue-engineered medical device according to claim 23 configured for use as a replacement for a cavopulmonary connection in human pediatric patients with hypoplastic left-heart syndrome.

31. The tissue-engineered medical device according to claim 23 configured for use as a heart valve or as a patch in a human pediatric patient with a defect of the cardiovascular system.

32. The tissue-engineered medical device of claim 23 configured for use in a treatment of a cardiovascular disease of a body of a human pediatric patient.

33. The tissue-engineered medical device according to claim 23 configured for use in a treatment of a defect of a cavopulmonary connection in a human pediatric patient.

34. A method for treating a human or animal patient, wherein the patient is suffering from a defect of a cardiovascular system, the method comprising the step of using the tissue-engineered medical device according to claim 23 as a heart valve or as a patch.

35. The method according to claim 34, wherein the patient is a human pediatric patient suffering from a defect of cavopulmonary connection.

36. The method according to claim 35, wherein the patient is a human pediatric patient suffering from hypoplastic left-heart syndrome.

37. The tissue-engineered medical device produced by the method according to claim 1, wherein the tissue-engineered medical device contains a polymer scaffold comprising a PGA-mesh which comprises a coating containing P4HB and an extracellular matrix developed on the polymer scaffold, and wherein the tissue-engineered medical device comprises all of the following features: an endotoxin content of less than 0.29 EU/ml; a mycoplasma content below a limit of detection; a residual DNA content of less than 50 ng dsDNA per mg dry weight; a residual water content of less than 5%; a PGA content of 0-30%, and a P4HB content of 30-75% (w/w); a hydroxyprolin content of more than 5 μg/mg; a content of fibronectin of at least 100 fmol/μg, and/or a content of collagen alpha-2(I) chain of at least 200 fmol/μg, and/or a content of collagen alpha-2(VI) chain of at least 5 fmol/μg; and/or a content of superoxide dismutase of less than 3 fmol/μg, and/or a content of 60S acidic ribosomal protein P2 of less than 3 fmol/μg, and/or a content of integrin alpha-5 of less than 3 fmol/μg a thickness of 0.15-700 μm; a suture retention of at least 0.5 N; a tensile strength of at least 0.5 MPa; a burst pressure of more than 150 mmHg.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) Preferred embodiments of the invention are described in the following with reference to the drawings, which are for the purpose of illustrating the present preferred embodiments of the invention and not for the purpose of limiting the same. In the drawings,

(2) FIG. 1 shows a systematic process overview of the production method according to the present invention, including various quality control steps;

(3) FIG. 2 shows pictures of the fabrication process of a tubular polymer scaffold for the production of a tissue-engineered medical device according to a first preferred embodiment in the form of a tissue-engineered vascular graft (TEVG), wherein in A, the forming of the mesh into a tube is shown; in B, the fusion of the overlapping edges is shown; in C, the spray coating of the tubular polymer scaffold is shown; and in D, the final tubular polymer scaffold on a mount prior to sterilization;

(4) FIG. 3 shows the seeding of the human cells on the inner surface of the tubular polymer scaffold of FIG. 2;

(5) FIG. 4 shows specifications for a pump flow program for the bioreactor phase;

(6) FIG. 5 shows thresholds of lactate measurement as a marker for cell performance during the bioreactor phase;

(7) FIG. 6 shows the details of the lyophilisation program preferably used;

(8) FIG. 7 shows the results of a material thickness analysis of a TEVG;

(9) FIG. 8 shows in A, a setup used for the suture retention test, and in B, the suture retention strength measured for the final TEVG;

(10) FIG. 9 shows in A, a setup used for the circumferential tensile strength test, in B, raw graphs of the circumferential tensile test, and in C, the circumferential tensile strength of the final TEVG indicated in MPa;

(11) FIG. 10 shows an experimental setting of a hydraulic burst pressure test, wherein in A, a schematic overview is shown, and in B, the fixation of the TEVG in the experimental setting is shown;

(12) FIG. 11 shows the results of the burst pressure testing (n=4) according to FIG. 10;

(13) FIG. 12 shows the hydroxyproline and proline content measured in sample TEVGs (n=5);

(14) FIG. 13 shows the results of shotgun MS analysis of sample TEVGs (n=12), followed by annotation of the detected peptides using gene ontology (GO) term 0031012 that allows to assign the peptides to the class of ECM-proteins, as well as Matrisome-annotation. Protein intensities (cps) of ECM-proteins are shown, as well as protein intensities of core-Matrisome and Matrisome-associated proteins;

(15) FIG. 14 shows the results of shotgun MS analysis of sample TEVGs followed by annotation using “Matrisome Project” categories, wherein protein intensities (cps) of the proteins that were assigned to the indicated classes, are shown;

(16) FIG. 15 shows the results of an MS analysis of ECM markers and decellularization markers in sample TEVGs, wherein in A, an absolute quantification of the indicated markers by using reference peptides of known concentration is shown, and in B, a relative quantification of the indicated markers is shown;

(17) FIG. 16 shows, in A, a size exclusion chromatography (SEC) of a sample TEVG to determine the PGA and P4HB content, and in B, the content of P4HB and PGA measured in the sample TEVG;

(18) FIG. 17 shows, in A, the pore radius, in B, the pore volume, and in C, the specific surface area measured in sample TEVGs (n=8);

(19) FIG. 18 shows hematoxylin/eosin (H&E) staining and Alcian blue staining of a sample TEVG (n=1);

(20) FIG. 19 shows a microCT analysis of a sample TEVG (n=1);

(21) FIG. 20 shows, according to a second exemplary embodiment of the invention, a PGA-mesh sutured into a nitinol sinus-stent prior to seeding and the resulting tissue engineered tri-leaflet heart valve after decellularization;

(22) FIG. 21 shows, according to a third exemplary embodiment of the invention, a PGA-mesh sutured onto a metal stainless steel ring prior to seeding and the resulting tissue engineered patch after decellularization.

DESCRIPTION OF PREFERRED EMBODIMENTS

(23) In FIG. 1, the systematic process overview shows the process steps for producing a polymer scaffold and isolating cells as preparatory processes. The products of these preparatory processes, i.e. the polymer scaffold and/or the isolated cells, can individually either be prepared as part of the inventive method of production of the TEMD, as further described below, or separately can be purchased or obtained otherwise for use in the method of production of the TEMD starting with the equilibration of the polymer scaffold and the expansion of the isolated cells to prepare both for the cell seeding step.

Example 1: Production of a Tissue-Engineered Vascular Graft

(24) Isolation and Expansion of Cells:

(25) Human umbilical cords (n=3) were collected after full-term births with informed consent according to the cantonal ethics commission of Zurich, Switzerland [KEK-ZH-2009-0095] and processed for isolation of venous fibroblasts according to established protocols.sup.13. The umbilical cord vein was isolated surgically and small tissue pieces were cut out using a dissecting scissors. Tissue pieces were placed on a sterile petri dish and were left to adhere to the bottom for 30+/−5 min. Culture medium was gently added and changed every third or fourth day. The preferred medium composition used for the first expansion of the isolated cells is as follows: 500 ml A-DMEM (Advanced-Dulbecco's Modified Eagle Medium), 50 ml. Fetal Bovine Serum (FBS), 5 ml Glutamax (200 mM), 1.25 ml Gentamycin (10 mg/ml). Tissue pieces were removed after first cellular outgrowth after approximately 1-2 weeks of incubation under humidified incubator conditions at 5% CO.sub.2 at 37° C.

(26) Scaffold Fabrication:

(27) FIG. 2, which relates to the production of a vascular graft (or a vascular graft comprising a valvular graft attached thereto/therein) according to a first exemplary embodiment of the present invention, shows the forming and soldering of a tubular polymer scaffold after the first coating step (not depicted) as well as the second coating step and the fixation of the tubular polymer scaffold on a mount. The scaffold substrates (scaffold patches) were fabricated from non-woven polyglycolic acid (PGA) meshes (specific gravity 60-80 mg/cm.sup.3; Confluent Medical Technologies, Warkwick, USA). The scaffold patches used had a rectangular shape of originally 6 cm×9 cm. Each PGA-mesh was coated in a defined two-step procedure. First, the PGA-mesh was dipped in a low-percentage solution of P4HB (1% poly-4-hydroxybutyrate (P4HB; TEPHA, Inc., USA) in a solution with the apolar solvent tetrahydrofuran (Sigma-Aldrich, Switzerland)) and the solvent was left to evaporate by air-drying for several hours. Next, the PGA-mesh was shaped to a tube by wrapping the mesh around a metallic cylinder with the required dimensions, i.e. radial diameter of 1.6 cm. The overlapping parts/edges of the coated PGA-mesh were fused by heating them to 80 degrees Celsius using a soldering-iron. The tube was then mounted on a holding device and coated on the outside with a low-percentage solution of P4HB (2% in tetrahydrofuran) by using a spraying device (airbrush pistol) in several steps. After the second coating step, the tubular polymer scaffold was shortened to a length of 8 cm (to adapt the size of the tubular polymer scaffold to the size of the holding device later used for placement in the bioreactor). The final composition of the polymer scaffold, i.e. the ratio of PGA to P4HB was determined by weighing of the polymer scaffold before and after coating with P4HB.

(28) The scaffold production steps are applicable to the production of all kinds of TEMD, however, the tube forming step is carried out only in case of the production of a vascular graft (or of a valvular graft if it is to be attached to or in the lumen of a vascular graft). The second coating step is advantageous for tubular scaffolds, and optional for non-tubular scaffolds, such as planar patches or grafts comprising only the valve replacement without any vessel-like portion. Accordingly, the P4HB coating is generally thinner on grafts which were only coated once instead of twice.

(29) The polymer scaffold was then packaged and ethylene oxide sterilized in 6±1% Ethylene oxide and 94±1% CO.sub.2 for 180 min at 45±3° C., ≥40% rel. humidity and 2.6±0.1 bar to obtain sterility. Sterilization was followed by an appropriate desorption/ventilation phase to remove residual ethylene oxide from the scaffold.

(30) Prior to seeding, the scaffold was equilibrated by pre-incubation for 12-72 hours in a cell culture medium enriched with ascorbic acid (vitamin C), having the following composition: 500 ml A-DMEM (Advanced-Dulbecco's Modified Eagle Medium), 50 ml Fetal Bovine Serum (FBS) (resulting in 9% (v/v)), 5 ml Glutamax (200 mM) (resulting in 1.8 mM), 0.5 ml Gentamycin (10 mg/ml) (resulting in 0.009 mg/ml), 0.63 ml Vitamin C (20%) (resulting in 0.225% (v/v)).

(31) The porosity of a sample polymer scaffold (DC16-90) was analyzed by Gas Adsorption analysis, i.e. the Brunauer-Emmett-Teller (BET) method, which applies to systems of multi-layer adsorption: Thereby, an average pore radius (BET) of 50 Angström was measured, at a specific surface area of 12 m.sup.2/g, and a total pore volume of 0.03 cm.sup.3/g.

(32) Cell Seeding:

(33) After pre-incubation/equilibration of the polymer scaffold, the isolated human fibroblasts were seeded onto scaffolds using a density of 2.2.-3.3 million cells/cm.sup.2.

(34) For this purpose, the cells were first suspended in purified fibrinogen (Sigma-Aldrich, Switzerland) (10 mg/mL of active protein), followed by addition of purified thrombin (Sigma-Aldrich, Switzerland). Per scaffold, 1.2 mg of fibrinogen and 1.2 U (units) of thrombin were used (ratio of 1:1), resulting in an optimal clotting time of approximately 5-8 minutes. Immediately after coagulation, the cell suspension was seeded onto the sterile scaffolds in a homogenous manner.

(35) In FIG. 3, a preferred pattern of application/seeding of the cell suspension on the inner (lumen-) cylindrical surface of a tubular polymer scaffold is shown. For this purpose, the mount was manually fixed with one hand and the other hand homogenously seeded the cell suspension on the inner surface of the mesh. Other patterns that achieve the desired homogenous distribution of cells are possible. The seeding steps are applicable to the production of all kinds of TEMD.

(36) After seeding, the seeded polymer scaffold was first incubated at static conditions for about 16 hours in the same cell culture medium as mentioned above, also enriched by addition of ascorbic acid (Vitamin C) as follows: 500 ml A-DMEM (Advanced-Dulbecco's Modified Eagle Medium), 50 ml Fetal Bovine Serum (FBS) (resulting in 9% (v/v)), 5 ml Glutamax (200 mM) (resulting in 1.8 mM), 0.5 ml Gentamycin (10 mg/ml) (resulting in 0.009 mg/ml), 0.63 ml Vitamin C (20%) (resulting in 0.225% (v/v)).

(37) Conditioning in Bioreactor:

(38) The seeded polymer scaffold was then placed on a holding device in a bioreactor and exposed to a pulsatile flux of incremental intensity over the next 21+/−4 days in the same above mentioned cell culture medium enriched by addition of ascorbic acid (Vitamin C). The conditioning during the bioreactor phase is applicable to the production of all kinds of TEMD.

(39) In FIG. 4, the specifications for a preferred pump flow program for a TEMD, especially for a TEVG are depicted, showing the generation of pulsatile flow by incremental increase of pumped volume during the bioreactor phase.

(40) FIG. 5 shows a table with minimum thresholds of lactate content in mmol/l at each medium change interval. Lactate serves as a marker for cell performance during the bioreactor phase. During the bioreactor phase, the ECM formation was verified by mass spectrometry, using Human Procollagen Type I C-Terminal Propeptide as a marker in the cell culture medium.

(41) After removal from the bioreactor, the TEVG of Example 1 was placed on a conduit stabilizer and incubated under static conditions for 12-36 hours in the same cell culture medium as in the bioreactor. This step is applicable also to the production of other types of TEMD.

(42) Decellularization:

(43) After incubation, the TEVG of Example 1 was decellularized. During decellularization, cells were lysed and removed using a washing solution that is composed as follows:

(44) TABLE-US-00001 Components Amount/Volume Final Concentration PBS 1000 ml EDTA (0.5M) 1.36 ml 0.68 mM Triton X-100 (100%) 2.5 ml 0.25% v/v Sodium-deoxycholate 2.5 g 0.25% w/v

(45) In a further step, the decellularized TEVG of Example 1 was treated with the nuclease benzonase in order to remove the DNA by enzymatic digestion. Prior to lyophilisation, the decellularized TEVG was rinsed in ddH.sub.2O to remove salts, cut to a length of 7 cm, and subsequently transferred to a 50 ml tube with a filter cap and then lyophilized (freeze dried). This decellularization step is applicable also to the production of other types of TEMD.

(46) Lyophilization:

(47) In FIG. 6, a preferred program for lyophilisation is depicted. This program prevents damaging of the material, e.g. due to crystal formation. The final product was double packaged in sterilization bags and sterilized by ethylene oxide treatment at an external company (QMedics). This lyophilisation step is applicable also to the production of other types of TEMD.

(48) Quality Control of TEVG:

(49) The final product, i.e. the decellularized, lyophilized and sterilized TEVG, was subjected to a quality control according to the following steps: verification of sterility; verification of endotoxin content; verification of mycoplasma content; verification of residual DNA; verification of residual water content; verification of polymer content; verification of hydroxyprolin content; verification of protein content: fibronectin, collagen alpha-2(I) chain, collagen alpha-2(VI) chain, decell-markers (superoxide dismutase, 60S acidic ribosomal protein P2, integrin alpha 5); measurement of thickness by microscopic analysis (dry/rehydrated); suture retention test; tensile strength test. These quality control steps are applicable also to the production of other types of TEMDs.

(50) A production batch of TEVG consisted of 6 grafts. One of them was cut apart for the production of representative samples and the pieces were separately packaged, lyophilized, and sterilized, parallel to the remaining 5 grafts. The pieces were then used for the various analyses, including sterility. For the purpose of testing, the packaging was removed again. The TEVG samples were analysed in a dried form after lyophilisation. For the biomechanical tests, the samples were rehydrated.

(51) The wall thickness of the TEVG was determined in a lyophilized state and after rehydration by a measuring microscope (Vision Engineering, HAWK 15-3) according ISO7198:2016 at Endolab Mechanical Engineering GmbH, Thansau/Rosenheim, Germany. Analysis of seven TEVG revealed an average thickness of 342+/−57 μm, as shown in FIG. 7. After rehydration for 20 minutes in 0.9% NaCl the wall thickness increased to by 16% to 397+/−64 μm. The measurement of wall thickness is applicable also to the production of other types of TEMDs.

(52) To assess further mechanical properties of a TEMD produced according to the method of the present invention, the circumferential tensile strength of the TEVG produced according to Example 1 was evaluated by using a tensile testing machine meeting the ISO 5081 requirements (Equipment used: Load cell, Instron, 2530-437; Universal testing machine, Instron, 5944). A sample of the final TEVG was cut normal to the long axis and the length of the sample (L) was measured. For the biomechanical analysis the sample was rehydrated for 20 min in 0.9% NaCl solution. The TEVG sample in its tubular form was placed onto two rounded pins (see FIG. 9A). The sample was stretched at a uniform rate of 100 mm/min until the break point was reached. The load at break was determined (T.sub.max) and the Circumferential Tensile Strength determined by the following formula: Circumferential tensile strength=T.sub.max/2*L. Tubular TEVG samples (n=5 of 3 different production runs) with an average length of 1.4 cm broke at an average load of 8.4 N, resulting in a circumferential strength of 0.29+/−0.05 N/mm. Based on the wall thickness of the samples a mean circumferential tensile strength of 0.87+/−0.21 MPa was calculated (See FIG. 9C).

(53) Hemodynamics by blood flow and blood pressure induce biomechanical forces on vessel walls. To assess the mechanical resilience of the TEVG, burst tests have been performed to evaluate the conditions under which rupture of the TEVG is induced. For this purpose, a complete TEVG of Example 1 was rehydrated for 20 min in 0.9% NaCl solution. After rehydration the vascular graft was applied to the test setup and exposed to increasing hydraulic pressures using distilled water as fluid element. During testing the pressure rise was recorded. The pressure was increased until the TEVG ruptured (see FIG. 10). At increasing hydraulic pressures, formation of small holes were observed. At hydraulic pressures of 264±52 mmHg rupture of the TEVG was observed (see FIG. 11).

(54) To determine the residual water content in the TEVG, a Karl Fischer titration according to Ph. Eur. 2.5.12 is performed. The residual water content in 7 TEVG derived from 5 different production batches was determined an in average 4.1+/−0.5% (w/w) (not depicted).

(55) The HYP-content in 5 TEVG (of three different production batches) was analyzed according to Ph. Eur. 2.2.56. and was in average 11.7+/−0.8 μg/mg (w/w; average+/−stdev) (see FIG. 12).

(56) In order to determine the proteineous composition of the decellulized TEVG, mass spectrometry (MS) analysis was performed. For this purpose, TEVG-samples were first digested (on-matrix protocol: protein reduction, alkylation and trypsin digestion) and subsequently acquired in shotgun LC-MS/MS mode. LC-MS/MS data were searched using a human UniProt database, and ECM proteins were annotated based on GO term 0031012 and with the “Matrisome Project” functional protein categories, in order to characterize the composition of the ECM present in TEVG in more detail (see FIG. 13). The Matrisome Project allows prediction of the ensemble of extracellular matrix and ECM-associated proteins (http://web.mit.edu/hyneslab/matrisome/). Protein annotation based on the “Matrisome Project” categories turned out to be more selective compared to GO term 0031012. The “Matrisome project” annotation also allows a classification of proteins in the following categories: ECM-glycoproteins; collagens; ECM-regulators; ECM-affiliated proteins; proteoglycans; secreted factors (see FIG. 14).

(57) The steps of assessment of further mechanical properties described above for the TEVG according to Example 1 is also applicable to the production of other types of TEMDs.

(58) In order to quantify markers for extracellular matrix present in TEVG in an absolute manner, reference peptides for three ECM marker proteins were used (collagen alpha-2(I) chain; collagen alpha-2(VI) chain and fibronectin). Furthermore, to demonstrate that the decellularization process during production of the TEVG worked effectively, reference peptides for three decellularization markers (60S acidic ribosomal protein P2; integrin alpha-5, and superoxide dismutase [Mn] mitochondrial)” were used. Absolute quantification of these ECM- and decellularization markers is depicted in FIG. 15A. Additional ECM- and decellularization markers were analysed, however this quantification is only relative since no reference peptides were applied for their quantification (see FIG. 15B). Altogether, the analysis of these ECM- and decellularization markers confirmed that the decellularization step performed during the production of the TEVG removes unwanted cellular components while it preserves the ECM.

(59) The TEMD according to the present invention is composed of human proteins (mainly ECM-proteins) and the biodegradable polymers poly-4-hydroxybutyrate (P4HB) and polyglycolic acid (PGA). The production of the inventive TEMD starts with the production of polymer scaffolds (composed of PGA and P4HB) that are subsequently seeded with cells. With seeding of cells on the polymer scaffold degradation of the polymers by hydrolysis is initiated, especially for the fast degrading PGA. In order to monitor the contents of the polymers in the final TEMD product, the polymers of the TEVG of Example 1 were extracted of the final product using an eluent and subsequently analyzed by size exclusion chromatography (SEC) at the contract company PSS Polymer Services GmbH, Mainz, Germany. Size exclusion chromatography characterized the molecular weight distribution of the extracts and by calibrating with pure samples of the polymer starting materials (PGA, P4HB; see FIG. 16A) of known concentration, the content of each polymer was evaluated in a semi-quantitative manner. Using this approach, a P4HB content of 40.7+/−4.6% (w/w) and a PGA content of 17.1+/−4.1% (w/w) was determined in the tested TEVG-samples (n=7 of five production batches; average+/−stdev) (see FIG. 16B).

(60) In the size exclusion chromatography (SEC) of a sample vascular graft to determine the PGA and P4HB content according to FIG. 16A, the content of PGA and P4HB was evaluated by spiking with pure polymer solutions (PGA or P4HB, indicated with arrows) of known concentrations.

(61) Gas adsorption analysis is commonly used for surface area and porosity measurements. This involves exposing solid materials to gases (Nitrogen gas is generally employed) at a variety of conditions and evaluating either the weight uptake or the sample volume. Analysis of these data provides information regarding the physical characteristics of the solid including: porosity, total pore volume and pore size. Porosity of the TEVG was determined by the method of Barrett, Joyner, and Halenda (BJH) which applies to the mesopore and small macropore size range. Results are depicted in FIG. 17.

(62) To analyze the structural composition of the TEVG and visualize particular components, standard histology analysis was performed at the Institut Mutualiste Montsouris (IMM), Paris, France. A hematoxylin/eosin (H&E) staining was used to visualize tissue structure and to confirm the absence of nuclei/DNA and an Alcian Blue staining was used to visualize glycosaminoglycans. Glycosaminoglycans are abundant in ECM and hence a marker for ECM. The representative H&E and Alcian blue stainings of the TEVG shown in FIG. 18 confirm the absence of nuclei and the presence of ECM, respectively. In both stainings the porous nature of the TEVG is discernible. The outside of the TEVG, that notably is composed of several layers of P4HB that are sprayed during the production of the polymer scaffold, are marked with the red arrow in FIG. 18.

(63) To analyse the wall thickness and structure of TEVG, X-ray microtomography (microCT) was performed (see FIG. 19). microCT uses x-rays to create cross-sections of a physical object that can be used to recreate a virtual model (3D model) without destroying the original object. The prefix micro-(μ) is used to indicate that the pixel sizes of the cross-sections are in the micrometre range.

(64) The quality control steps described above are applicable to the production of other types of TEMDs.

(65) Implantation of the TEVG:

(66) Implantation of the TEVG of Example 1 is to be performed by anastomosis to the IVC (vena cava inferior) and pulmonary artery by suture ligation. To assess the mechanical stability and, thus safety of the suture, suture retention tests have been performed. For this purpose, a suture (string made of stainless steel with the diameter of 0.14 mm, which corresponds to prolene 5/0 suture) was inserted 2 mm from the end of a rehydrated TEVG sample through one wall of the device to form a half loop (see FIG. 8A). The suture was pulled at a rate of 100 mm/min and the force required to pull the suture through the device was recorded (Equipment used: Load cell, Instron, 2530-437; Universal testing machine, Instron, 5944). Suture retention strength of 7 TEVG was measured and in average a force of 0.82+/−0.25 N (corresponding to 82 g) had to be applied to pull the suture through the device (see FIG. 8B). The assessment of mechanical stability mentioned above is also applicable to the production of other types of TEMDs.

Example 2: Production of a Tissue-Engineered Sinus Valve

(67) According to a second exemplary embodiment of the present invention, a tri-leaflet heart valve scaffold was made from a non-woven PGA mesh and finally integrated into a nitinol sinus-stent by using continuous sutures (as shown in FIG. 20). The PGA-scaffold was coated with 1% P4HB, overnight dried, and sterilized with EtOH, Pen-Strep (Penicillin-Streptomycin; 10,000 U/ml), and amphothericine. Finally, the PGA-scaffold was incubated overnight at 37° C. with an optimized growth medium comprising advanced DMEM supplemented with 1% Pen-Strep Solution, 1% Glutamax, 10% FBS and 130 mg Vit. C (per 500 ml).

(68) Thereafter, the valve was seeded with human dermal fibroblasts (1×10.sup.6 cells/cm.sup.2) using fibrin as a cell carrier. After seeding, the scaffold was placed, preferably in a closed configuration of the leaflets, into a dual pulse duplicator system for 4 weeks of culture. During valve culture, inserts were used to impose a physiological valve geometry. Vit. C or TGF-β were used as optional supplements in the medium to enhance ECM production. The decellularization process was performed as described for Example 1.

(69) The sinus valve, being designed for the replacement of a respective sinus valve in the pulmonary artery, serves as an example for the production of heart valve replacement grafts.

Example 3: Production of a Tissue-Engineered Patch

(70) According to a second exemplary embodiment of the present invention, a PGA-scaffold was cut (circular or strip) and coated with 1% P4HB. After overnight drying, the patch was sutured onto a metal stainless steel ring (as shown in FIG. 21) and sterilized with EtOH, Pen-Strep, and amphothericine. Next, the patch was incubated overnight at 37° C. with an optimized growth medium comprising advanced DMEM supplemented with 1% Pen-Strep Solution, 1% Glutamax, 10% FBS and 130 mg Vit. C (per 500 ml). Thereafter, human dermal fibroblasts were seeded onto the patch using fibrin as a cell carrier. After seeding, the patch was placed in small medium jar and cultured for 4 weeks by using an orbital shaker to enhance medium distribution. Also for the production of the patch, Vit. C or TGF-β were used as optional supplements in the medium to enhance ECM production. The decellularization process was performed as described for Example 1.

REFERENCES

(71) 1. Langer, R. & Vacanti, J. P. Tissue Engineering. Science 260, 920-926, doi:DOI 10.1126/science.8493529 (1993). 2. Asti, A. & Gioglio, L. Natural and synthetic biodegradable polymers: different scaffolds for cell expansion and tissue formation. Int J Artif Organs 37, 187-205, doi:10.530/ijao.5000307 (2014). 3. Dunn, A. S., Campbell, P. G. & Marra, K. G. The influence of polymer blend composition on the degradation of polymer/hydroxyapatite biomaterials. J Mater Sci Mater Med 12, 673-677 (2001). 4. Sugiura, T. et al. Tropoelastin inhibits intimal hyperplasia of mouse bioresorbable arterial vascular grafts. Acta Biomater 52, 74-80, doi:10.1016/j.actbio.2016.12.044 (2017). 5. Mol, A. et al. Autologous human tissue-engineered heart valves: prospects for systemic application. Circulation 114, 1152-158, doi:10.1161/CIRCULATIONAHA.105.001123 (2006). 6. Weber, B. et al. Injectable living marrow stromal cell-based autologous tissue engineered heart valves: first experiences with a one-step intervention in primates. Eur Heart J 32, 2830-2840, doi:10.1093/eurheartj/ehr059 (2011). 7. Li, H., Du, R. & Chang, J. Fabrication, characterization, and in vitro degradation of composite scaffolds based on PHBV and bioactive glass. J Biomater Appl 20, 137-155, doi:10.1177/0885328205049472 (2005). 8. Chen, G. Q. & Wu, Q. The application of polyhydroxyalkanoates as tissue engineering materials. Biomaterials 26, 6565-6578, doi:10.1016/j.biomaterials.2005.04.036 (2005). 9. Shinoka, T. et al. Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiov Sur 115, 536-545, doi:Doi 10.1016/S0022-5223(98)70315-0 (1998). 10. Schmidt, D., Stock, U. A. & Hoerstrup, S. P. Tissue engineering of heart valves using decellularized xenogeneic or polymeric starter matrices. Philos Trans R Soc Lond B Biol Sci 362, 1505-1512, doi:10.1098/rstb.2007.2131 (2007). 11. Hoerstrup, S. P. et al. Functional living trileaflet heart valves grown in vitro. Circulation 102, III44-49 (2000). 12. Weber, B. et al. Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model. Biomaterials 34, 7269-7280, doi:10.1016/j.biomaterials.2013.04.059 (2013). 13. Hoerstrup, S. P. et al. Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells. Ann Thorac Surg 74, 46-52; discussion 52 (2002). 14. Hoerstrup, S. P. et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur. J. Cardiothorac. Surg. 2003; 23:1002-6. 15. Agrawal C. M. et al., Biodegradable polymeric scaffolds for musculoskeletal tissue engineering. J. Biomedic. Mat. Res. 2001; 55:141-50. 16. Niklason et al., Functional arteries grown in vitro, Science, 1999; 284: 489-93. 17. D. Schmid, S. P. Hoerstrup, “Tissue engineered heart valves based on human cells”, Swiss Med. Wkly. 2005; 135: 618-623.